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Summary
 
During HIV/SIV infection, there is widespread programmed cell death in infected and, per-
haps more importantly, uninfected cells. Much of this apoptosis is mediated by Fas–Fas ligand
(FasL) interactions. Previously we demonstrated in macaques that induction of FasL expression
and apoptotic cell death of both CD4
 
1
 
 and CD8
 
1
 
 T cells by SIV is dependent on a functional
 
nef
 
 gene. However, the molecular mechanism whereby HIV-1 induces the expression of FasL
remained poorly understood. Here we report a direct association of HIV-1 Nef with the 
 
z
 
chain of the T cell receptor (TCR) complex and the requirement of both proteins for HIV-
mediated upregulation of FasL. Expression of FasL through Nef depended upon the integrity of
the immunoreceptor tyrosine-based activation motifs (ITAMs) of the TCR 
 
z
 
 chain. Confor-
mation for the importance of 
 
z
 
 for Nef-mediated signaling in T cells came from an indepen-
dent finding. A single ITAM motif of 
 
z
 
 but not CD3
 
e
 
 was both required and sufficient to pro-
mote activation and binding of the Nef-associated kinase (NAK/p62). Our data imply that Nef
can form a signaling complex with the TCR, which bypasses the requirement of antigen to ini-
tiate T cell activation and subsequently upregulation of FasL expression. Thus, our study may
provide critical insights into the molecular mechanism whereby the HIV-1 accessory protein
Nef contributes to the pathogenesis of HIV.
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I
 
n HIV/simian immunodeficiency virus (SIV)
 
1
 
 infection,
the 
 
nef
 
 gene plays a key role in viral replication and pro-
gression of disease. This is based on studies in macaques and
humans, who remain asymptomatic or long-term nonpro-
gressing when infected with an SIV mutant lacking a 
 
nef
 
gene or HIV with multiple 
 
nef
 
 deletions, respectively (1–3).
More recently, a study using a transgenic mouse model has
demonstrated that Nef harbors a major determinant for
HIV-induced pathogenicity (4). Despite the considerable
importance of Nef for HIV/SIV pathogenesis, its function
at the molecular level is poorly understood. At least three
in vitro effects of Nef have been described. Nef downregu-
lates the surface receptors CD4 and MHC I (5, 6), increases
viral infectivity (7), and stimulates T cell signaling pathways
(8–10).
The major consequence of HIV infection is the deple-
tion of T cells leading to immunoparesis characteristic of
AIDS. This is likely due to the widespread programmed
cell death (apoptosis) induced by HIV (11–13). Several dif-
ferent apoptotic pathways have been proposed in HIV in-
fection, including Fas/FasL (14), TNF/TNFR (15), and an
interaction between TNF-related apoptosis-inducing ligand
(TRAIL) and its receptors (16). In HIV-infected patients,
there is upregulation of both Fas and FasL as well as an
 
increased susceptibility of CD4
 
1
 
 and CD8
 
1
 
 cells to Fas-
mediated killing (17–21). Recently, we have demonstrated
in macaques that induction of FasL expression and apop-
totic cell death of both CD4
 
1
 
 and CD8
 
1
 
 T cells by SIV is
dependent on a functional 
 
nef
 
 gene (22). However, a mo-
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lecular mechanism integrating this observation into other
documented effects of Nef is lacking.
The concept of Nef interfering with early events ema-
nating from the TCR could explain its dual effects on T cell
activation and FasL expression, since both functions are
regulated by the TCR complex (23–25). Here we report
that HIV-mediated upregulation of FasL in T cells is de-
pendent on the association of Nef with the TCR 
 
z
 
 chain.
By demonstrating that Nef directly targets the TCR of the
infected cell, we provide novel insight into the molecular
function of Nef in HIV infection.
 
Materials and Methods
 
Cell Lines and Antibodies.
 
Generation of Jurkat cell lines con-
stitutively expressing CD8 tag or CD8-Nef chimeras was described
recently (8, 26). Jurkat, J.CaM.1 (Lck
 
2
 
), J.45.01 (CD45
 
2
 
), and
J.RT3-T3.5 (TCR
 
2
 
) cells were provided by Arthur Weiss (Univer-
sity of California, San Francisco, CA [27]). J.RT3-T3.5 cells express-
ing various CD16
 
z
 
 constructs or coexpressing CD8-Nef were gen-
erated by electroporation using puromycin and neomycin for
selection. Stable clones were enriched for protein expression by
magnetic anti-CD16/anti-CD8 beads. The mAbs against the AU-5/
AU-1 epitope and FasL (NOK-1) were purchased from Hiss Diag-
nostics and PharMingen.
 
Plasmid Constructions.
 
Generation of the CD8-Nef (SF2) and
CD16
 
z
 
/
 
e
 
 chimeras as well as COOH-terminal–tagged Nef (AU-1)
was described previously (8, 26, 28). Fusion proteins between
CD16 and individual 
 
z
 
 ITAMs (ITAM 1, amino acids [aa] 1–70;
ITAM 2, aa 70–110; ITAM 3, aa 110–141) were generated as
described previously (28). The mutations in CD16
 
z
 
 as well as in
Nef/CN.94 were generated by a two-step PCR procedure and
cloned into the pRcCMV expression vector (Invitrogen). In
CD16
 
z
 
mu, the tyrosine residues in three ITAM motifs (two tyro-
sine residues in each ITAM) were mutated to alanines. In
CN.94PXmu/Nef.PXmu, the FPVR motif of Nef (aa 72–75) was
mutated to VRIT. Construction of the proviral clone NL4-3,
containing the SF2 
 
nef
 
 gene (NL4-3.SF2Nef), as well as the Nef-
negative construct (NL4-3
 
D
 
Nef), was described previously (26).
For the generation of recombinant baculoviruses, the “bac to bac”
system was used (Bio-Rad Laboratories).
 
Protein Expression Assays.
 
Transfections into 293T cells, meta-
bolic labeling with 
 
35
 
S-Translabel, immunoprecipitation, West-
ern blot, and in vitro kinase assays were performed as described
previously (8, 26). The immunoprecipitates were washed three
times (wash buffer: 1% NP-40, 450 mM NaCl, 50 mM Tris-HCl
[pH 8], 1 mM EDTA). To show an interaction between Nef and
 
z
 
, extraction and washing buffers contained 1% Brij instead of 1%
NP-40. FasL promoter activity was tested as described previously
(29) by cotransfection of pFasL-Luc (provided by Xiangdong Liu,
Department of Virus and Cancer, Aarhus, Denmark) with CD8-
Nef constructs or pCTax as positive control (provided by Ralph
Grassman, Institute of Virology, Erlangen, Germany). All trans-
fections were performed in duplicate by mixing 6 
 
m
 
l of lipo-
some reagent (DMRIE-C; GIBCO BRL) and 2 
 
m
 
g of each
plasmid for 2 
 
3 
 
10
 
6
 
 Jurkat or Jurkat mutant cells.
 
In Vitro HIV Infection of Jurkat or Jurkat Mutant Cell Lines.
 
Cells (5 
 
3 
 
10
 
6
 
) were superinfected with 1 ml of HIV IIIB (1.6 
 
3
 
10
 
4
 
 cpm/ml, reverse transcriptase [RT] activity), NL4-3.SF2.Nef
(2.4 
 
3 
 
10
 
4
 
 cpm/ml, RT activity), or NL4-3
 
D
 
Nef (2.5 
 
3 
 
10
 
4
 
cpm/ml, RT activity) for 2 h. After infection, cells were washed
and adjusted to a concentration of 10
 
6
 
/ml and incubated for an
additional 48 h. Cell culture supernatants were collected on day 5
for analysis of p24 by ELISA or RT activity by Quan-T-RT kit
(Amersham Pharmacia Biotech).
 
Analysis of FasL Expression by Flow Cytometry and Immunoprecip-
itation.
 
To assess cell surface FasL expression on HIV-infected
cells or transiently transfected Jurkat TAg cells, the metallopro-
tease inhibitor BB2116 (British Biotech [30]) was added to the
medium 4–6 h before the assay to enhance cell surface FasL ex-
pression. In brief, cells were stained with 20 
 
m
 
l of biotin-conju-
gated anti–human FasL mAb (NOK-1; PharMingen) followed by
5 
 
m
 
l of PE-conjugated streptavidin (Sigma). Labeled cells were
analyzed on a FACScan™ (Becton Dickinson). Isotype-specific
mAbs of irrelevant specificity were used as negative controls
(Dako Diagnostics). To assess expression of whole FasL protein,
 
35
 
S-labeled cells (5 
 
3 
 
10
 
6
 
) were immunopreciptatied for FasL using
anti-FasL–specific mAb (NOK-1) as described previously (30).
 
Results
 
Requirement of the TCR 
 
z
 
 Chain for Binding of Nef-associated
Kinase (p62) to Nef.
 
As shown previously, Nef associates
with a serine kinase, termed p62 or Nef-associated kinase
(NAK [31]). The Nef–NAK interaction is complex: Nef
stimulates the phosphorylation/activation of NAK, and it is
only in this activated form that NAK can bind Nef (32).
This suggests that Nef must act upstream of NAK to pro-
mote NAK activation. Our previous results showing that
Nef interfered with early signals emanating from the TCR
suggested it may interact with a component of the TCR
signaling complex. This prompted us to study Nef-medi-
ated NAK/p62 activation in cell lines with TCR signaling
defects. CD8-Nef chimeras (CD8-Nef), containing the ex-
tracellular domain of CD8
 
a
 
 fused to Nef, were stably trans-
fected into wild-type Jurkat and a variety of Jurkat mutant
cell lines lacking either Lck (J.CaM.1), CD45 (CD45
 
2
 
), or
the entire TCR signaling complex (RT3.T3.5). Expression
of CD8-Nef in these cell lines was verified by metabolic la-
beling and immunoprecipitation (Fig. 1 B). The Nef chi-
meras from these transfectants were immunoprecipitated
and subjected to an in vitro kinase assay. NAK/p62 associa-
tion was observed in all cell lines except the TCR
 
2
 
 cells
(Fig. 1 A). The latter result was confirmed in a second, in-
dependently transfected cell clone (data not shown).
Next we asked whether NAK binding could be restored
in cells lacking the TCR complex by stable transfection
with TCR-
 
z
 
 or CD3
 
e
 
 fused to the extracellular domain of
CD16 (CD16
 
z
 
 and CD16
 
e
 
). These TCR subcomponents
contain signaling motifs (immunoreceptor tyrosine-based T
cell activation motifs [ITAMs]), which are required and
sufficient for T cell activation (28, 33). After obtaining sin-
gle cell clones, expression of the chimeras was verified by
metabolic protein labeling and FACS
 
®
 
 analysis (data not
shown). In several attempts, we were unable to coexpress
CD8-Nef (CN) with CD16
 
z
 
 in TCR
 
2
 
 cells. Cell clones
that were obtained either showed no detectable CN or
CD16 expression or died rapidly. The effect resembled ac-
tivation-induced cell death (AICD) by Nef as reported pre-
viously (8). Coexpression of CN and CD16
 
e
 
 was achieved;
however, the obtained cell clones had a low CN as well 
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as CD16 surface expression (Fig. 1 D, lane 3). Therefore,
we constructed 
 
z
 
 chimeras containing the three individual
 
z
 
 ITAMs in isolation (CD16
 
z
 
1, 2, or 3; see Materials and
Methods for details). In a seperate construct, the tyrosine
residues in all three YXXL motifs of CD16
 
z
 
 were mutated
to alanines (CD16
 
z
 
mu). We failed to coexpress the first
 
z
 
 ITAM with Nef. However, NAK/p62 binding to Nef
was reestablished in the TCR
 
2
 
 cells by coexpression with
the second or third ITAM of 
 
z
 
 (Fig. 1 C, lanes 4 and 5). In
these latter cell lines, expression of CD16
 
z
 
1 and 2 as well as
CD8-Nef decreased significantly over time (data not shown),
indicating that coexpression of both proteins was not favor-
able. The difficulties regarding the coexpression of the in-
dividual 
 
z
 
 ITAMs with CD8-Nef may be explained by
studies published by Combadiere et al. (34) showing that in
particular the first 
 
z
 
 ITAM but much less the second and
third are capable of inducing apoptosis when activated. The
signaling-defective 
 
z
 
 chain (CD16
 
z
 
mu) expressed well, but
NAK binding to Nef was greatly reduced (lane 6). No
NAK/p62 binding was observed by coexpression of CD3
 
e
 
(lane 3). Since NAK binding to Nef was not completely
negative with CD16
 
z
 
mu, the Nef–
 
z
 
 complex may recruit
additional signaling molecules to the plasma membrane which
are important for NAK activation. Assuming that the ef-
fects of the first 
 
z
 
 ITAM would be similar to ITAM 2 and 3,
it appeared that at least one functional ITAM of the CD3 
 
z
 
chain was required for binding of p62/NAK to Nef.
The functional link between Nef, 
 
z
 
, and NAK was con-
firmed by transient transfection assays in a heterologous sys-
tem. As shown in Fig. 1 E, cotransfection of CD16
 
z
 
 (lanes 4
and 5) but not CD16
 
e
 
 (lanes 2 and 3) significantly increased
binding of p62/NAK to Nef. A minimal increase was seen
after cotransfection of CD16
 
z
 
mu (lanes 6 and 7), which
paralleled the small effect seen in Fig. 1 C, lane 6. Thus, no
other T cell–specific components except the functional
ITAM(s) from the TCR 
 
z
 
 chain, were required for NAK
activation and NAK/Nef association in 293T cells.
 
Direct Association of Nef with the TCR 
 
z
 
 Chain.
 
Full-length
CD8-Nef when expressed at the cell membrane promotes
AICD. Upon stable transfection, cell clones are preferen-
tially selected in which Nef is predominantly expressed in
the cytoplasm, where it does not exert such a detrimental
effect on cell survival. In contrast, NH
 
2
 
-terminal fragments
of Nef are expressed at high levels at the plasma membrane
where TCR-
 
z is located (8). These NH2-terminal frag-
ments can recruit a complex of proteins to form the NH2-
terminal kinase complex, which binds between amino acids
20 and 35, and may contribute to T cell activation (26).
The NH2 terminus also has a conserved domain containing
a proline-rich motif (PxxP, aa 73–82) known to associate
with SH3 domains of tyrosine kinases (35). We reasoned
that these domains/motifs could interact with and bind
TCR-z. To prove a direct interaction, coimmunoprecipi-
tation experiments were performed using stable cell lines
with different CD8-Nef chimeras (Fig. 2, A and B). The
only interaction was seen with a construct expressing the
NH2-terminal 94 amino acids of Nef containing the PxxP
motif (lane 4). Underscoring the importance of the PxxP mo-
tif for z binding, we found that point mutations in the PxxP
motif of the 94–amino acid Nef construct (CN.94.PXmu)
almost completely abolished z binding (lane 5).
Further evidence for an interaction between Nef and z
was obtained by coimmunoprecipitation of Nef and z from
Hi5 insect cells coinfected with recombinant baculoviruses
(Fig. 2 D). CD16z was found to coprecipitate with Nef
(Fig. 2 D, lane 3), but not with Nef.PXmu (lane 6). To
confirm the specificity of the interaction, aliquots of the
anti-z immunoprecipitates were incubated with Jurkat
(z-containing) or the TCR2 (z-lacking) cytoplasmic lysates.
Wild-type Jurkat competed for Nef binding (lane 4),
whereas the TCR-z–negative cytoplasmic lysates did not
(lane 5). The reduced Nef signal in lane 5 may be explained
by the reduced amount of immunoprecipitated z (Fig. 2 E,
lane 5). Additional evidence for the interaction of both
Figure 1. Requirement of the TCR z chain for binding of NAK/p62 to Nef. (A) In vitro kinase assay after immunoprecipitation (IP) of CD8-Nef
chimeras using the CD8 tag from stably transfected wild-type and mutant Jurkat cell lines lacking Lck, TCR, or CD45. Lane 1, control (Cont.) Jurkat
transfected with the CD8 tag. (B) Control immunoprecipitation showing expression of 35S-labeled CD8-Nef. (C) In vitro kinase assay after immunopre-
cipitation of CD8-Nef to study NAK/p62 association/phosphorylation in wild-type (Cont., lane 1) and TCR2 Jurkat cell lines (lane 2), and after coex-
pression (stable transfection) of CD8-Nef with either CD16e, CD16z2 (ITAM 2), CD16z3 (ITAM 3), or CD16zmu (mutation of all three ITAMs) in
the TCR2 cell line (lanes 3–6). (D) Control immunoprecipitation of 35S-labeled CD8-Nef from cell lines shown in C. (E) In vitro kinase assay after im-
munoprecipitation of AU-1–tagged Nef from transiently transfected 293T cells. Lane 1, transfection with Nef alone; lanes 2–7, cotransfection with in-
creasing amounts (0.5 and 1 mg) of CD16e, CD16z, or CD16zmu. (F) The nitrocellulose filter shown in E was blotted (WB) with an anti-Nef (AU-1)
antibody to verify comparable Nef expression.1492 Interaction of Nef with TCR-z Induces FasL Expression
proteins was obtained by coimmunoprecipitation after
transient transfection into COS cells and subsequent in
vitro kinase assay (data not presented).
Upregulation of FasL Expression by HIV Requires Both Intact
Nef and TCR z Chain. We have previously shown that
the upregulation of FasL in SIV infection requires an intact
nef gene (22). In general, the level of cell surface FasL expres-
sion is quite low when analyzed by FACS® even when met-
alloproteinase inhibitors are used which block cleavage of
FasL from the cell surface. In view of this difficulty, we used
additional experimental approaches to analyze Nef-mediated
FasL expression (see below). Since stimulation of TCR-z ef-
fectively upregulates FasL expression (34, 36), we speculated
that the interaction of Nef with TCR-z would lead to a sim-
ilar effect. First, to show that HIV-Nef is required for FasL
upregulation, we infected Jurkat with wild-type HIV (NL4-
3.SF2Nef) or a mutant lacking the nef gene (NL4-3DNef)
(Fig. 3). Little if any FasL is seen on cells infected with Nef-
deleted HIV, thus confirming our previous results with SIV.
The level of viral replication in Jurkat cells was comparable,
as determined by RT activity (NL4-3.SF2Nef, 4.6 3 103
cpm; NL4-3DNef, 5.8 3 103 cpm). Upregulation of FasL by
HIV is also lost in mutant Jurkat cells lacking the TCR com-
plex, whereas cells reconstituted with z but not with the z
mutant restored the FasL expression upon HIV infection as
determined by both immunoprecipitation (Fig. 4 A) and
FACS® analysis (Fig. 4 B). Viral replication assessed by p24
assay indicated that these cell lines were comparably infected
(wild-type, 3.5 6 0.5; TCR2, 3.8 6 1.0; CD16z, 3.8 6 0.5;
CD16zmu, 3.1 6 0.25 ng/ml).
Nef Can Induce FasL Expression in the Presence of TCR-z.
To investigate a direct upregulation of FasL by Nef, a
CD8-Nef construct not capable of binding z (Nef.PXmu;
see Fig. 2 B) and CD8-Nef were transiently expressed in
Jurkat cells and analyzed for FasL upregulation. CD8-Nef
but not the Nef mutant led to a significant cell surface ex-
pression of FasL (Fig. 5). Next, FasL upregulation was stud-
ied in Jurkat and TCR mutant cell lines using a FasL pro-
motor/luciferase reporter construct. The latter has been
shown to be stimulated in transient assays by the HTLV I
Tax protein (29). Nef stimulated the FasL promotor in Jur-
kat and TCR2 mutant cells reconstituted with the TCR z
Figure 2. Association of membrane-associated
Nef with the TCR z chain. (A) Anti-Nef (CD8)
immunoprecipitation, then anti-z Western blot
(WB). (B) Anti-z immunoprecipitation, then
anti-Nef Western blot from wild-type Jurkat
cells stably transfected with CD8 tag (Cont.),
and CD8-Nef chimeras containing full-length
Nef expressed in the cytoplasm (CD8.Nef.cyt.),
the NH2-terminal 49 amino acids of Nef (CD8-
Nef.49), the NH2-terminal 94 amino acids
(CD8-Nef.94), and CD8-Nef.94PXmu in which
the PxxP motif has been mutated. (C) Control
immunoprecipitation of CD8.Nef chimeras from
35S-labeled cells to show a comparable protein ex-
pression (*). (D) Nef–z association after baculovi-
rus coinfection of Hi5 cells. Control anti-Nef
Western blot (WB) after anti-Nef (AU-1) immu-
noprecipitation from Hi5 cells infected with
wild-type Nef or Nef with a mutated PxxP motif
(lanes 1 and 2). Immunoprecipitated Nef from Hi5 cells ran, in addition to monomers (Nef-m), as dimers (Nef-d) or higher order multimers (arrows), which
may be important for Nef function. Hi5 cells were then coinfected with wild-type Nef and z fused to CD16 (CD16z; lanes 3–6). CD16z was immunopre-
cipitated using an AU-5 tag, and the immunoprecipitates were blotted for Nef (AU-1). Two immunoprecipitations were performed in the presence of cyto-
plasmic lysates from Jurkat (z-positive; lane 4) or TCR-z–negative cells (lane 5). The positions of the antibody heavy (*) and light (**) chains are indicated.
(E) Control Western blot. The nitrocellulose filter shown in D was stripped and blotted with an antibody recognizing the CD16z construct (AU-5).
Figure 3. Nef is required for FasL upregulation. Jurkat cells were in-
fected with (A) wild-type HIV-1 (NL4-3.SF2Nef) or (B) SF2 lacking the
nef gene (NL4-3DNef). After 48 h, FasL expression (solid line) was as-
sessed by flow cytometry and compared with staining with a control mAb
(dashed line). The level of viral replication in Jurkat cells was comparable
as determined by RT activity (NL4-3.SF2Nef, 4.6 3 103 cpm; NL4-
3DNef, 5.8 3 103 cpm).1493 Xu et al.
chain. No effect was seen using the Nef.PXmu construct or
the TCR2 Jurkat cell line (Fig. 6). These assays confirmed
that a functional Nef protein and the TCR z chain were
both required and sufficient to upregulate FasL in T cells.
Discussion
In general, the interaction between Fas and FasL plays a
important role in the homeostatic regulation of normal im-
mune responses (37). Stimulation of the TCR–CD3 complex
in T cells causes upregulation of FasL and eventually leads to
AICD or apoptosis (23–25). A key molecule in this process is
the TCR z chain and the three ITAMs contained therein.
Cross-linking of the z chain or constructs containing individ-
ual z ITAMs alone were found to be sufficient to induce
T cell activation and Fas-mediated apoptosis (28, 35, 36). In
agreement with these findings, we have shown here that
TCR-z as well as the functional integrity of the ITAM sig-
naling motifs of z were required for HIV-mediated upregula-
tion of FasL. However, these findings further implied that
HIV targets the TCR z chain directly through a viral protein.
To date, several lines of evidence indicated that the Nef
Figure 4. FasL upregulation by
HIV requires the TCR z chain.
FasL expression was assessed 48 h
after infection with HIV (IIIB
strain) by immunoprecipitation
using an anti-FasL mAb (A) or
by flow cytometry (B). Wild-
type (WT) and TCR2 Jurkat are
compared with the TCR2 cells
stably transfected with CD16z or
CD16zmu (signaling-defective
CD16z). The level of viral repli-
cation in Jurkat cells was compa-
rable as determined by p24 assay
(wild-type, 3.5 6 0.5; TCR2,
3.8  6 1.0; CD16z, 3.8 6 0.5;
CD16zmu, 3.1 6 0.25 ng/ml).
Figure 5. Induction of FasL expression by Nef or a Nef mutant
(Nef.PXmu). Jurkat cells were transfected with CD8-Nef or CD8-
Nef.PXmu (no binding to TCR-z) construct by electroporation and kept
under neomycin selection for 2 wk. Outgrowing cells were selected for
CD8 surface expression by Dynabeads and analyzed for FasL expression
by FACS® as described above.
Figure 6. Upregulation of FasL by Nef requires TCR-z. Transient
cotransfection of a FasL promotor/luciferase reporter with an empty vec-
tor (cont.; negative control), Tax (positive control), Nef, and Nef.PXmu
into Jurkat (WT), TCR2 Jurkat (TCR2), and TCR2 cells reconstituted
with CD16-z (TCR2/Zeta). The expression of the reporter gene was de-
termined as described in Materials and Methods. Bars, the mean 6 SD of
three experiments.1494 Interaction of Nef with TCR-z Induces FasL Expression
protein exerted such a role. First, Nef-mediated activation
of T cells has been demonstrated in a number of reports (8–
10). Second, expression of Nef in the cytoplasm of T cells
interferes with early T cell signaling events emanating from
the TCR–CD3 complex, including hypophosphorylation
of TCR-z, whereas expression of a plasma membrane–
associated form of Nef causes AICD in Jurkat cells (8).
Third, a very aggressive form of Nef from SIV, SIV-YE-
Nef, basically functions like an ITAM domain of TCR-z
(38). Finally, SIV-induced upregulation of FasL in T cells
depends on the expression of an intact Nef protein (22), and
Nef from a lethal SIV strain (smmPBj14) alone can directly
cause FasL upregulation (39). Thus, it appeared very likely
that Nef acted at the level of the TCR. Indeed, our study
confirms this assumption by showing that Nef can directly
interact with the TCR z chain.
Strong evidence for the interaction of Nef with z came
from a second, surprising finding. In Jurkat cells lacking the
TCR, binding of the Nef-associated serine kinase p62/NAK
was abolished. Conversely, reconstitution of these cells with
the z ITAM 2 and 3 restored binding of p62/NAK with Nef.
Furthermore, the integrity of the ITAM motif appeared to be
important, since mutation of the z ITAMs greatly reduced the
effect. As shown previously, the p62/NAK kinase has to be
activated in order to bind to Nef (32). These results suggest a
dynamic interaction of Nef with the z ITAMs, ultimately re-
sulting in the activation of p62/NAK, which in turn binds to
Nef. In view of our and other studies, it is likely that activation
of p62/NAK is part of Nef-mediated stimulation of T cell sig-
naling pathways; however, at this point it is not clear whether
p62/NAK has a role in the Nef-mediated upregulation of
FasL. Notably, Nef binds to p62/NAK in cells lacking a TCR
(31; e.g., COS cells). In these cells, the TCR z chain may be
functionally replaced by other receptors, possibly containing
ITAMs. This would explain why Nef has effects in cells usu-
ally not infected by HIV (40; e.g., NIH 3T3 cells).
More recently, Howe et al. showed that Nef from SIV
or HIV-2 associated with the TCR z chain but failed to
show an interaction with HIV-1 Nef (41). Our study dif-
fers from that of Howe et al. in at least two respects. First
we made constructs to target Nef to the plasma membrane
where the TCR is located. Second, we have established
functional consequence of the Nef–z interation which may
have relevence to the pathogenesis of HIV interaction.
Induction of cell death by HIV could be mediated by dif-
ferent viral proteins. Cross-linking of CD4 by HIVgp120 in
the presence of Tat protein can induce FasL expression and
apoptosis of uninfected T cells (42). Additionally, interac-
tion of HIVgp120 with chemokine receptor CXCR4 on
macrophages leads to death of CD81 T cells mediated by
TNF–TNFRII interaction (15). In this study, we report an
additional important mechanism of HIV-mediated apopto-
sis by demonstrating that Nef directly interacts with TCR-z
and that both molecules are required for HIV-mediated up-
regulation of FasL. The interaction between Nef and TCR-z
forms a signaling complex, bypassing the requirement for
TCR ligation by antigen, and allowing HIV/SIV to activate
T cells and upregulate FasL expression on the infected cells.
Thus, upregulation of FasL by Nef on HIV- or SIV-
infected cells may, like FasL expression at sites of immune
privilege and on some tumors, allow infected cells to evade
the immune response. In addition, the effect of immune
evasion is enhanced by Nef-mediated downregulation of
surface MHC class I and CD4 expression (5, 6, 22, 43–46;
see Fig. 7). Taken together, our results provide additional
insights into the molecular mechanism whereby the HIV
accessory protein Nef regulates T cell activity and contrib-
utes to the pathogenesis of HIV.
Figure 7. Model describing mechanisms
of immune evasion mediated by the HIV nef
gene. Nef is expressed in the early viral life
cycle and, after myristoylation, associates
with the plasma membrane where several
protein interactions take place. Nef interacts
with z, which leads to the activation of p62/
NAK, which in turn causes the binding of
p62/NAK to Nef. These events ultimately
stimulate FasL expression, which may protect
infected cells from CTL attack by killing
Fas1 viral-specific CTLs in the process (1).
Nef can also downregulate MHC class I ex-
pression and protect the infected cells against
killing by CTLs (2), or CD4 expression lead-
ing to loss of CD4 T cell function (2).1495 Xu et al.
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